Roger Connor

President, Global Vaccines

Roger Connor
Roger Connor

Roger Connor - download image from Flickr (JPG)

As President of GSK Global Vaccines, Roger Connor oversees an industry-leading enterprise delivering vaccines to over 160 countries and more than £5 billion in turnover. Roger has been a member of the Corporate Executive Team since 2013 and was appointed to his current role on 1 September 2018.

GSK Vaccines has a broad portfolio of more than 40 vaccines and a robust pipeline of 14 candidate vaccines in development. The Vaccines team is made up of over 17,000 employees across 11 countries working to deliver more than 2 million doses every day to help protect people throughout life all around the world.

In addition to his Vaccines duties, he is responsible for GSK’s global procurement organisation.

Previously, Roger was President, Global Manufacturing & Supply (GMS), leading an organisation of over 30,000 people, and a network of over 60 Pharmaceutical and Consumer Healthcare manufacturing sites. He also led Procurement, Product Quality, and Environment, Health, Safety & Sustainability at a corporate level.

Prior to his role in GMS, Roger was Vice President, Office of the CEO and Corporate Strategy from February 2010. In this role, he served as secretary to the CET, as well as having responsibility for developing the GSK long-range financial forecast, related analyses and benchmarking for CET, and integrating the key transformation initiatives that were under way across GSK.

Roger joined GSK in 1998 from AstraZeneca and has worked in a number of roles within finance and manufacturing strategy, including GSK sites at Cork, Ireland as well as Ware and Barnard Castle in the UK.  

He holds a Degree in Mechanical and Manufacturing Engineering from Queen’s University, Belfast and a Masters in Manufacturing Leadership from Cambridge University. He is also a qualified Chartered Accountant, having trained with PriceWaterhouseCoopers.